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Seamless Scalability, Consistency and Quality of Transient Protein Production in 
CHO Cells By Using MaxCyte Flow Electroporation Technology 
Weili Wang, Rama Shivakumar, Pachai Natarajan, Angelia Viley, Madhusudan Peshwa, 
James Brady  
MaxCyte Inc., 22 FirstField Road, Gaithersburg, Maryland 20878, USA 
Recombinant protein production often suffers from process inconsistencies as cell cultures are 
scaled up. High levels of process consistency and scalability are important not only for GMP stage 
manufacturing, but they are also critical for early stage R&D studies since good predictivity of any scale 
production can shorten timelines and minimize costs. There are many parameters that influence 
consistency of production during scale up. These include agitation rates, dissolved oxygen levels and pH. 
Consistency of production following transient gene expression (TGE) is further impacted by process 
variabilities that are inherent to many transient transfection methodologies. The aim of this study is to 
show how MaxCyte’s flow electroporation technology (STX technology) can transiently produce 
therapeutic materials from milligram to gram scales quickly to support early to mid-stage drug 
development. We collected data on cell growth, viability and productivity post electroporation, 
demonstrating that this technology is highly consistent and scalable (from 0.5 x 106 to 2 x 1011 cells of 
transfected cells) Antibody titers from 1 g/L up to 2.7 g/L were achieved by transient gene expression in 
CHO-S cells. Furthermore, we showed that TGE materials have the comparable protein quality as proteins 
produced by a stable cell line. The high TGE productivity, product quality and scalability in CHO cells by 
using MaxCyte transfection technology can accelerate the drug development process and reduce the risk 
of drug evaluation and selection. 
